CANC ETF holdings (NASDAQ) - Page 2 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

SNDX Syndax Pharmaceuticals Inc 2.8 M 127.4 K 1.7%

CGON CG oncology Inc 2.7 M 45.9 K 1.7%

ZLAB Zai Lab Ltd 2.3 M 121.3 K 1.5%

ERAS Erasca Inc 2.3 M 169.5 K 1.4%

ZYME Zymeworks Inc 2.3 M 96.7 K 1.4%

LEGN Legend Biotech Corp 2.2 M 115.4 K 1.4%

NUVB Nuvation Bio Inc 2.1 M 362.0 K 1.3%

HALO Halozyme Therapeutics Inc 2.1 M 29.9 K 1.3%

Chugai Pharmaceutical Co Ltd 2.1 M 30.7 K 1.3%

SMMT Summit Therapeutics Inc 1.8 M 110.9 K 1.2%

ANAB AnaptysBio Inc 1.6 M 28.7 K 1.0%

NRIX Nurix Therapeutics Inc 1.6 M 97.6 K 1.0%

REGN Regeneron Pharmaceuticals Inc 1.5 M 1 982.0 1.0%

CRVS Corvus Pharmaceuticals Inc 1.5 M 82.1 K 0.9%

URGN UroGen Pharma Ltd 1.5 M 67.2 K 0.9%

RLAY Relay Therapeutics Inc 1.5 M 142.0 K 0.9%

GILD Gilead Sciences Inc 1.4 M 9 272.0 0.9%

OLMA Olema Pharmaceuticals Inc 1.4 M 56.6 K 0.9%

D

DAWN Day One Biopharmaceuticals Inc 1.3 M 121.9 K 0.8%

ARGX Argenx SE 1.3 M 1 663.0 0.8%

1
2
3

Notícias

GNOM, CANC, IBB: Use Targeted Healthcare ETFs to Build Wealth - TipRanks.com

Here's Why Biotech ETFs Are Rallying Hard

Be Thankful to These ETFs This Year

Inside the Recent Strength in Biotech ETFs

Biotech ETFs Bounce Back in 2025: Here's Why